Sentences with phrase «current grant cycle»

Applications must be received by June 1 or December 1 to be eligible for the current grant cycle.

Artist Grant, International Call for Applicants: Current Grant Cycle, Grant to One Visual Artist Deadline: October 15th, 2017 From their call: Artist Grant provides a one - time $ 500 USD grant to one visual artist each grant cycle.

on Artist Grant, International Call for Applicants: Current Grant Cycle, Grant to One Visual Artist

Artist Grant provides a one - time $ 500 USD grant to one visual artist each grant cycle.The deadline for the current grant cycle is July 31, 2017.

The current grant cycle deadline is October 15, 2017.

The current grant cycle deadline is January 15, 2018.

Not exact matches

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Budget limited to no more than amount of current parent award; Can be from less than $ 5,000 to more than $ 100,000 depending on career level of candidate; End with competitive cycle of parent grant

If it appears that an inappropriate Conflict of Interest exists, the Vice President of Scientific Affairs, in consultation with the chairs of the Board Grants Committee and appropriate Scientific Review Committee, may recommend the proposal for additional Stage I review in the current review cycle, or offer to pass the proposal directly to stage II review in a future review cycle.

For the current funding cycle, the AACTE Board of Directors has allocated a total of $ 50,000 for the grant program, of which $ 40,000 is for «Chapter Activities» and $ 10,000 is for «Chapter Development.»

Location: Middle Tennessee / Nashville Priority: Appropriate and Equitable Resources and Supports Topic: Teacher and student voice on reducing discipline disparities Summary: The funding for the Oasis Center, MNPS, and PASSAGE builds on the previous grant cycle of work that focused on educating current MNPS teachers on cultural competency, and implicit bias in order to promote the equitable treatment of students in MNPS schools.